Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months

NCT03598270 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT03598270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Phase 3
Overall status
Completed
Start date
November 21, 2018
Completion date
August 5, 2024
Enrollment
417 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ovarian carcinoma